Financials
Financial year 2025
Scaldis Pharma from Aalst, company number BE0803923429, closed financial year 2025 with a result of € -14,039 after tax. For that financial year Scaldis Pharma recorded a gross margin of € 54,532 and equity of € 5,697. Compared with financial year 2024, the result moved from € 24,009 to € -14,039. The company made a loss. The buffer shrank hard: equity is 84 % below last year. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 30, 2026.
€ 5,697
▼ 84% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -14,039
▼ still € 24,009 profit in 2024
Profit after tax over the fiscal year.
€ 20,602
▼ 32% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € 697.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
€ 30,736
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 1,145
▼ 21% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 211,366
€ 28,468 is repaid this year. At this pace the long-term loan is gone in ≈ 7 years.
€ 4,145
▲ € 3,758 vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 10,329
▼ 33% vs 2024
Taxes, VAT and social contributions still to pay.
| 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|
| Gross margin | € 9,087 | € 36,248 | € 54,532 | ▲ 50% |
| Profit after taxes | € 5,727 | € 24,009 | € -14,039 | ▼ € 38,047 |
| Equity | € 10,727 | € 34,735 | € 5,697 | ▼ 84% |
| Total debts | € 24,701 | € 16,106 | € 245,464 | ▲ € 229,358 |
| Cash | € 14,916 | € 30,386 | € 20,602 | ▼ 32% |
| Land & buildings | - | - | € 48,600 | |
| Retained profit | € 5,727 | € 29,735 | € 697 | ▼ 98% |
| Dividend | € 0 | € 0 | € 15,000 | |
| Bank debt | € 0 | € 0 | € 211,366 | |
| Balance sheet total | € 35,427 | € 50,842 | € 251,161 | ▲ € 200,319 |
By gross margin, Scaldis Pharma ranks 1st of 4 companies with main activity “Activiteiten van ingenieurs en aanverwante technische adviseurs, exclusief landmeters-experts” in Aalst that publish figures (fiscal year 2025).
Key figures of Scaldis Pharma, fiscal years 2023 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
Ask about Scaldis Pharma the way you would ask their accountant.
Answers from the filed annual accounts, the Belgian Official Gazette and the CBE register.
Connect ChatGPT or Claude for free- ChatGPT
- Claude
Free account, no payment card. Key figures unlimited, the annual accounts and deeds of 10 companies a month. Need more? Get in touch, we are looking for our first pilot users.
What happened to Scaldis Pharma?
What happened at Scaldis Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 14,039 (▼ € 38,047 vs 2024). Source: NBB ↗
- Incorporation, published in the Gazette. Source: Staatsblad ↗
- New establishment in Aalst. KBO
- Maxim Van Den Steen became a director. NBB
In short
From € 5,727 profit in 2023 to € 14,039 loss in 2025.
Paid € 10,365 in corporate taxes since 2023.
Best year ever: 2024, with € 24,009 profit.
Paid out € 15,000 in dividends to the owners in total.
Management
Behind Scaldis Pharma is Maxim Van Den Steen.
Directors
According to the 2025 annual accounts
Maxim Van Den Steen
Director
since 2023
Establishments
Establishment units
Physical locations of this company
Kapittelstraat 75
9310 Aalst
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Similar companies in Aalst
Same main activity (Activiteiten van ingenieurs en aanverwante technische adviseurs, exclusief landmeters-experts), 3 active companies in Aalst, largest first.
€ 47,632 gross margin · 2025
€ 9,480 gross margin · 2025
€ -4,685 gross margin · 2025
Shareholders according to the Official Gazette deeds
Who contributed at incorporation and at capital increases, with the deed as source. Later share transfers are not published in the Gazette.
Incorporation
Source: Deed ↗- Van den Steen Maxim(oprichter) 100%
Details
- Company number
- 0803.923.429
- VAT number
- BE 0803.923.429
- Registered office
- Kapittelstraat 75, 9310 Aalst
- Names & denominations
- Scaldis Pharma
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 13 July 2023
- Peppol
- Active · Active since 21 Oct 2026
- Activities · NACE
Activiteiten van ingenieurs en aanverwante technische adviseurs, exclusief landmeters-experts
Vervaardiging van geneesmiddelen